Inclusion Criteria:

- Provision of signed and dated, written informed consent prior to any study specific
procedures

- Male or female, aged 18 years and older

- Histologically or cytologically proven diagnosis of prostate cancer, squamous non
small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC), or a known
PTEN-deficient solid malignancy, that is refractory to standard therapies

- Females should be using adequate contraceptive measures (see Section 4.3), should not
be breast feeding and must have a negative pregnancy test prior to start of dosing if
of child-bearing potential

- World Health Organisation (WHO)/ECOG performance status 0 to 1 with no deterioration
over the previous 2 weeks and minimum life expectancy of 12 weeks

Exclusion Criteria:

- Treatment before study with (a) Nitrosourea or mitomycin C; (b) Investigational
agents from a previous clinical study; (c) Chemotherapy, immunotherapy or anticancer
agents; (d) hormonal therapy (e.g., steroids)

- Treatment before study with (a) Strong inhibitors and strong or moderate inducers of
CYP3A4 (b) Radiotherapy with a wide field of radiation

- With the exception of alopecia or toxicities related to the use of
gonadotropin-releasing hormone agonists any unresolved toxicities from prior therapy
greater than Common Terminology Criteria for Adverse Events grade 1 at the time of
study treatment

- Spinal cord compression or brain metastases unless asymptomatic, treated and stable
and not requiring steroids

- Any evidence of severe or uncontrolled systemic diseases including active liver
disease (other than malignancy), active bleeding diatheses, or active infection
including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).